Letter to the Editor in Response to “Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta‐Analysis” by Nishii et al.

Documenti analoghi

• Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta‐Analysis
  di: Yasufumi Nishii, et al.
  Pubblicazione: (2025)
• Effects of Histamine H 3 Receptor Antagonist/Inverse Agonist Pitolisant on Temporal Prediction, Spatial Switching, and Spontaneous Locomotion in Mice
  di: Shohei Kaneko, et al.
  Pubblicazione: (2026)
• Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta‐Analysis
  di: Minoru Urata, et al.
  Pubblicazione: (2025)
• The Impact of Adjunctive Aripiprazole on Olanzapine‐Induced Metabolic Adverse Effects in Patients With Schizophrenia: A Systematic Review
  di: Stephen Simmons, et al.
  Pubblicazione: (2025)
• Neurobiology of COVID‐19‐Associated Psychosis/Schizophrenia: Implication of Epidermal Growth Factor Receptor Signaling
  di: Hiroyuki Nawa, et al.
  Pubblicazione: (2025)